Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Medscape

FDA Okays New Indications for Once-Weekly Growth Hormone

Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
PharmaTimes

FDA approves once‑weekly Sogroya for wider paediatric use

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...
Endocrinology Advisor

Sogroya Approval Expanded to Include 3 Additional Pediatric Growth Disorders

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Novo Nordisk receives FDA approval for Sogroya in three new pediatric indications

Investing.com -- Novo Nordisk announced late Friday that the US Food and Drug Administration has approved three new indications for once-weekly Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 ...
Medscape

Daily Oral Option for Acromegaly Wins EU Backing

Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.
조선일보

South Korea fuels growth-shot boom as heightflation rises and side-effect fears grow

On the 25th, in front of a growth clinic in Seocho District, Seoul. A 10-year-old girl surnamed Park came out after finishing a consultation with her grandmother. The grandmother repeatedly told her ...

Is Peptide Stacking the Cure-All for Bouncier Skin?

Peptides have been in the skincare spotlight for some time—dubbed the ‘silent powerhouse’, the skin-restoring ingredient improves barrier health and elasticity. But beyond the bottle, they’re now ...

Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...
MedPage Today on MSN

Once-Weekly Treatment Approved for Achondroplasia in Kids

Navepegritide is indicated for those ages 2 and older with open epiphyses ...